miR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by Inhibiting CXCL11

References

• Desille-Gbaguidi H, Avigdor S, Body G, Ouldamer L. Survival impact of primary site surgery on metastatic breast cancer patients at diagnosis. J Gynecol Obstet Hum Reprod. 2019;48(3):171–177. doi:10.1016/j.jogoh.2018.10.01430352310
   PubMed Web of Science ®Google Scholar
• Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307–316. doi:10.1056/NEJMoa190376531166679
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–469. doi:10.1200/JCO.1999.17.2.46010080586
   PubMed Web of Science ®Google Scholar
• Ahmad A. Breast Cancer Statistics: recent Trends. Adv Exp Med Biol. 2019;1152:1–7.31456176
   PubMed Web of Science ®Google Scholar
• Hendrick RE, Baker JA, Helvie MA. Breast cancer deaths averted over 3 decades. Cancer. 2019;125(9):1482–1488.30740647
   PubMed Web of Science ®Google Scholar
• Guanghui R, Xiaoyan H, Shuyi Y, Jun C, Guobin Q. An efficient or methodical review of immunotherapy against breast cancer. J Biochem Mol Toxicol. 2019;33(8):e22339.31157481
   PubMed Web of Science ®Google Scholar
• Li Z, Xu R, Li N. MicroRNAs from plants to animals, do they define a new messenger for communication? Nutr Metab. 2018;15:68.
   Google Scholar
• Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ. 2015;22(1):22–33.25190144
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.14744438
   PubMed Web of Science ®Google Scholar
• Zhou Y, Dang J, Chang KY, et al. miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. Cancer Res. 2016;76(19):5777–5787. doi:10.1158/0008-5472.CAN-15-293627698189
   PubMed Web of Science ®Google Scholar
• Du Z, Wu J, Wang J, et al. MicroRNA-1298 is downregulated in non-small cell lung cancer and suppresses tumor progression in tumor cells. Diagn Pathol. 2019;14(1):132. doi:10.1186/s13000-019-0911-431801557
   PubMed Web of Science ®Google Scholar
• Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492–520. doi:10.1210/er.2006-004417475924
   PubMed Web of Science ®Google Scholar
• Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(11):1882–1890. doi:10.1002/ibd.2131220848514
   PubMed Web of Science ®Google Scholar
• Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009;8(5):379–383. doi:10.1016/j.autrev.2008.12.00219105984
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu H, Si L, et al. MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate. 2018;78(7):479–490. doi:10.1002/pros.2346829542173
   PubMed Web of Science ®Google Scholar
• Gao YJ, Liu L, Li S, et al. Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition. Onco Targets Ther. 2018;11:7333–7343. doi:10.2147/OTT.S16787230425523
   PubMed Web of Science ®Google Scholar
• Wei X, You X, Zhang J, Zhou C. MicroRNA-1305 Inhibits the Stemness of LCSCs and Tumorigenesis by Repressing the UBE2T-Dependent Akt-Signaling Pathway. Mol Ther Nucleic Acids. 2019;16:721–732. doi:10.1016/j.omtn.2019.04.01331128423
   PubMedGoogle Scholar
• Liu X, Jin G, Qian J, et al. Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer. World J Surg Oncol. 2018;16(1):82. doi:10.1186/s12957-018-1380-z29685151
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–7. doi:10.1093/nar/gkt124824297251
   PubMed Web of Science ®Google Scholar
• Li G, Sun L, Mu Z, et al. MicroRNA-1298-5p inhibits cell proliferation and invasion of bladder cancer via downregulating connexin 43. Biochem Cell Biol. 2019.
   Google Scholar
• Zhang Y, Zhao W, Li S, et al. CXCL11 promotes self-renewal and tumorigenicity of alpha2delta1(+) liver tumor-initiating cells through CXCR3/ERK1/2 signaling. Cancer Lett. 2019;449:163–171. doi:10.1016/j.canlet.2019.02.01630771435
   PubMed Web of Science ®Google Scholar
• Barrow-McGee R, Procter J, Owen J, et al. Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. J Pathol. 2019:2.
   Web of Science ®Google Scholar
• Camargo MC, Song M, Shimazu T, et al. Circulating Inflammation Markers and Risk of Gastric and Esophageal Cancers: A Case-Cohort Study Within the Japan Public Health Center-Based Prospective Study. Cancer Epidemiol Biomarkers Prev. 2019;28(4):829–832. doi:10.1158/1055-9965.EPI-18-115730877129
   PubMed Web of Science ®Google Scholar
• Kundu N, Ma X, Brox R, et al. The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem Cells. Breast Cancer. 2019;13:1178223419873628. doi:10.1177/117822341987362831619923
   PubMed Web of Science ®Google Scholar
• Bauer D, Mazzio E, Soliman KFA. Whole Transcriptomic Analysis of Apigenin on TNFalpha Immuno-activated MDA-MB-231 Breast Cancer Cells. Cancer Genomics Proteomics. 2019;16(6):421–431. doi:10.21873/cgp.2014631659097
   PubMed Web of Science ®Google Scholar
• Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267(2):271–285. doi:10.1016/j.canlet.2008.03.01818439751
   PubMed Web of Science ®Google Scholar
• Soria G, Yaal-Hahoshen N, Azenshtein E, et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine. 2008;44(1):191–200. doi:10.1016/j.cyto.2008.08.00218790652
   PubMed Web of Science ®Google Scholar
• Soria G, Ofri-Shahak M, Haas I, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011;11(1):130. doi:10.1186/1471-2407-11-13021486440
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–1131. doi:10.1158/2326-6066.CIR-14-016025480554
   PubMed Web of Science ®Google Scholar
• Dominguez C, McCampbell KK, David JM, Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. 2017;2(21):21. doi:10.1172/jci.insight.94296
   Web of Science ®Google Scholar
• Kaplanov I, Carmi Y, Kornetsky R, et al. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116(4):1361–1369. doi:10.1073/pnas.181226611530545915
   PubMed Web of Science ®Google Scholar
• Brummer G, Acevedo DS, Hu Q, et al. Chemokine Signaling Facilitates Early-Stage Breast Cancer Survival and Invasion through Fibroblast-Dependent Mechanisms. Mol Cancer Res. 2018;16(2):296–308. doi:10.1158/1541-7786.MCR-17-030829133591
   PubMed Web of Science ®Google Scholar
• Kitamura T, Pollard JW. Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacological Research. 2015;100:266–270. doi:10.1016/j.phrs.2015.08.00426275794
   PubMed Web of Science ®Google Scholar
• Svensson S, Abrahamsson A, Rodriguez GV, et al. CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. Clin Cancer Res. 2015;21(16):3794–3805. doi:10.1158/1078-0432.CCR-15-020425901081
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Wang E, Marincola FM. Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome. Oncoimmunology. 2014;3(4):e28727. doi:10.4161/onci.2872725340012
   PubMed Web of Science ®Google Scholar
• Holm NT, Abreo F, Johnson LW, Li BDL, Chu QD. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat. 2009;113(2):293–299. doi:10.1007/s10549-008-9921-818270814
   PubMed Web of Science ®Google Scholar
• Schott AF, Goldstein LJ, Cristofanilli M, et al. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer. Clin Cancer Res. 2017;2(21):5358–5365. doi:10.1158/1078-0432.CCR-16-2748
   Web of Science ®Google Scholar
• Schmidt M, Weyer-Elberich V, Hengstler JG, et al. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018;20(1):15.29482642
   PubMed Web of Science ®Google Scholar
• Masuda T, Noda M, Kogawa T, et al. Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer. Cancer Sci. 2020;111(3):924–931.31943636
   PubMed Web of Science ®Google Scholar